Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Sarcoma 2Ovarian Neoplasms 2Melanoma 2Waldenstrom Macroglobulinemia 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Squamous Intraepithelial Lesions 1Sezary Syndrome 1Sarcoma, Kaposi 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Pain 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Keratosis, Actinic 1

Interventions

tremelimumab 4Cystoscopy 3durvalumab 2avelumab 2Paclitaxel 2Gemcitabine 2Docetaxel 2Cisplatin 2vocimagene amiretrorepvec 1vinflunine 1trebananib 1trastuzumab duocarmazine 1pegfilgrastim 1merphos 1infigratinib 1erdafitinib 1efineptakin alfa 1copanlisib 1atezolizumab 1Vinblastine 1Trastuzumab 1Taxes 1TAS-116 1Specimen Handling 1Sirolimus 1Rosiglitazone 1Ropivacaine 1Rogaratinib 1Radiotherapy 1Polymerase Chain Reaction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Urinary Bladder Neoplasms × Celecoxib × Clear all
NCT00084578 2013-07-15

Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder

Fox Chase Cancer Center

Phase NA Withdrawn
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡